Unii-A3ulp0F556 Good Manufacturer supply High Quality 219685-50-4
- Molecular Formula:
- Molecular Weight:0.00000
- PSA:0.00000
- LogP:0.00000
Unii-A3ulp0F556 (219685-50-4) Usage
Eculizumab, a fully humanized anti-C5 monoclonal antibody, was introduced for treating patients with PNH to reduce hemolysis. It is the first therapy to be approved for this rare and life-threatening form of hemolytic anemia. PNH is a clonal hematopoietic stem-cell disorder that is characterized by the production of abnormal red blood cells (RBCs) with a deficiency of surface proteins that protect the cells against attack by the body’s complement system. Complement-mediated destruction of the susceptible RBCs results in intravascular hemolysis, the primary clinical manifestation in all PNH patients. Previously, patients with PNH have mainly been managed supportively, with red cell transfusions as required, and treatments such as folate and iron supplementation, anticoagulation for thrombotic disease, and the occasional use of steroids during hemolytic crises. Allogenic stem cell transplantation is currently the only curative option for PNH; however, it is associated with significant morbidity and mortality. Eculizumab therapy is aimed at preventing red cell lysis through blockade of complement activation process and the production of the membrane attack complex. Eculizumab specifically binds to the human complement protein C5 with high affinity (IC50 = 2 nM) and inhibits its cleavage to C5a and C5b, which is a key step in the pathway leading to the membrane attack complex C5b-C9.Eculizumab has been granted orphan drug status from both the FDA and European regulatory agencies.The most serious adverse reaction associated with eculizumab therapy is meningococcal infections. Eculizumab is contraindicated in patients who are not vaccinated against Neisseria meningitidis or who have N. meningitidis infections. The most common adverse reactions with eculizumab include headache (44%), nasopharyngitis (23%), back pain (19%), and nausea (16%).
How to get the best price on Unii-A3ulp0F556?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of Unii-A3ulp0F556 . You can buy high quality, low price Unii-A3ulp0F556 219685-50-4 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
![](/UploadCKEDITOR/a4bd98d7-ecb3-4177-b750-e29205fb8b8f.jpg)
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches